Acorda Therapeutics Inc (NASDAQ: ACOR) closed the day trading at $2.50 down -81.44% from the previous closing price of $13.47. In other words, the price has decreased by -$10.8200 from its previous closing price. On the day, 3699296 shares were traded.
Ratios:
For a better understanding of ACOR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.26 and its Current Ratio is at 0.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on June 17, 2021, Upgraded its rating to Buy and sets its target price to $10 from $5 previously.
On August 14, 2019, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $31 to $6.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACOR now has a Market Capitalization of 16.73M and an Enterprise Value of 170.35M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.03. Its current Enterprise Value per Revenue stands at 1.53 whereas that against EBITDA is 3.87.
Stock Price History:
Over the past 52 weeks, ACOR has reached a high of $24.20, while it has fallen to a 52-week low of $8.98. The 50-Day Moving Average of the stock is 13.9918, while the 200-Day Moving Average is calculated to be 13.4702.
Shares Statistics:
Over the past 3-months, ACOR traded about 4.03K shares per day on average, while over the past 10 days, ACOR traded about 375.8k shares per day. A total of 1.24M shares are outstanding, with a floating share count of 1.23M. Insiders hold about 0.69% of the company’s shares, while institutions hold 12.69% stake in the company. Shares short for ACOR as of Mar 15, 2024 were 9.46k with a Short Ratio of 2.35, compared to 10.25k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.76% and a Short% of Float of 0.77%.
Earnings Estimates
Current recommendations for the stock of the company come from 0 analysts. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
Revenue Estimates
Based on 1 analysts’ estimates, the company’s revenue will be $163.09M in the next fiscal year. The high estimate is $163.09M and the low estimate is $163.09M. The average revenue growth estimate for next year is up 17.40% from the average revenue estimate for this year.
